Lipidbrick® IM21.7c Cationic Lipids for LNP Formulation

Supplier: Polyplus-transfection
Lipidbrick®
101000173 101000172 101000232 101000172 101000173 101000232
CA76645-732EA 1747.02 CAD
CA76645-732 CA76645-734 CA77552-846 77552-846 76645-734 76645-732
Lipidbrick® IM21.7c Cationic Lipids for LNP Formulation
Transfection Reagents
LipidBrick® IM21.7c is a novel cationic lipid dedicated to the formulation of lipid nanoparticles (LNPs) for the development of mRNA-based vaccines and therapeutics. LipidBrick® IM21.7c overcomes the challenges posed by the current generation of ionizable lipids used in LNPs, allowing for wider in vivo biodistribution and reduced accumulation in the liver. Proof-of-concept work has demonstrated that the intrinsic properties of LipidBrick® IM21.7c in modulating the overall electrical charge of LNPs extend the in vivo biodistribution and improve both drug efficacy and formulation stability without inducing safety concerns.

  • Efficient: Modulate LNP properties to adapt the biodistribution depending on the therapeutic purpose
  • Secure: Use a unique lipid structure protected by an independent patent owned by Polyplus®
  • Accelerate your project: in vitro and in vivo proof of concept have been successfully performed
  • Colored

Formula: C₅₉H₁₁₇ClN₂
Molecular weight: 890.03
Synonyms: LipidBrick ; IM21.7c
GHS Symbol(s): GHS07
GHS Signal Word: Warning

Classification according to Regulation (EC) No 1272/2008: Acute toxicity, Oral (Category 4), H302, H312, H332.
Skin Irrit. (Category 2), H315.
Eye Irrit. (Category 2), H319.
Specific target organ toxicity, single exposure;Respiratory system (Category 3), H335.

Color: White to off-white.
Identity: Conform to reference spectra.

Packaging: Glass bottle with rubber stopper and polypropylene screw cap.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR